Meta-level question: how do you evaluate evidence for oxandrolone when the human data is thin and most trials are small?
The comparison group matters more than the compound when the outcome is something as fuzzy as focus.
Two weeks is not enough time to attribute anything to a compound unless the effect is dramatic.
Most of the popular protocols are borrowed from clinical populations and applied to healthy people without comment.
Haematocrit creep is the boring one that catches people at the six week mark.
Posting to be argued with, mainly.
A plausible mechanism is not an outcome, and this class is the textbook example.
A certificate of analysis answers one question and gets quoted as though it answers four.
I would take the narrow conclusion. Broad ones are more interesting and less true.
Narrow conclusion, briefly right. Broad conclusion, interestingly wrong. I know which I keep choosing.
Three questions kill most of the confidence in a thread like this: sample size, blinding, who paid.
Log dose, time and sleep. Ten seconds a day and it turns the anecdote into something you can look at.